191 related articles for article (PubMed ID: 22937108)
1. Mild electrical stimulation and heat shock ameliorates progressive proteinuria and renal inflammation in mouse model of Alport syndrome.
Koga T; Kai Y; Fukuda R; Morino-Koga S; Suico MA; Koyama K; Sato T; Shuto T; Kai H
PLoS One; 2012; 7(8):e43852. PubMed ID: 22937108
[TBL] [Abstract][Full Text] [Related]
2. Mild electrical stimulation with heat shock attenuates renal pathology in adriamycin-induced nephrotic syndrome mouse model.
Teramoto K; Tsurekawa Y; Suico MA; Kaseda S; Omachi K; Yokota T; Kamura M; Piruzyan M; Kondo T; Shuto T; Araki E; Kai H
Sci Rep; 2020 Oct; 10(1):18719. PubMed ID: 33128027
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor-α drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis.
Ryu M; Mulay SR; Miosge N; Gross O; Anders HJ
J Pathol; 2012 Jan; 226(1):120-31. PubMed ID: 21953121
[TBL] [Abstract][Full Text] [Related]
4. STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model.
Yokota T; Omachi K; Suico MA; Kamura M; Kojima H; Fukuda R; Motomura K; Teramoto K; Kaseda S; Kuwazuru J; Takeo T; Nakagata N; Shuto T; Kai H
Nephrol Dial Transplant; 2018 Feb; 33(2):214-223. PubMed ID: 28992339
[TBL] [Abstract][Full Text] [Related]
5. Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome.
Ning L; Suleiman HY; Miner JH
Am J Physiol Renal Physiol; 2021 Jul; 321(1):F12-F25. PubMed ID: 34029143
[TBL] [Abstract][Full Text] [Related]
6. Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.
Ding F; Wickman L; Wang SQ; Zhang Y; Wang F; Afshinnia F; Hodgin J; Ding J; Wiggins RC
Kidney Int; 2017 Dec; 92(6):1515-1525. PubMed ID: 28754557
[TBL] [Abstract][Full Text] [Related]
7. Renal, auricular, and ocular outcomes of Alport syndrome and their current management.
Zhang Y; Ding J
Pediatr Nephrol; 2018 Aug; 33(8):1309-1316. PubMed ID: 28864840
[TBL] [Abstract][Full Text] [Related]
8. Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling.
Morino S; Kondo T; Sasaki K; Adachi H; Suico MA; Sekimoto E; Matsuda T; Shuto T; Araki E; Kai H
PLoS One; 2008; 3(12):e4068. PubMed ID: 19114996
[TBL] [Abstract][Full Text] [Related]
9. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome.
Yokota T; Omachi K; Suico MA; Kojima H; Kamura M; Teramoto K; Kaseda S; Kuwazuru J; Shuto T; Kai H
PLoS One; 2017; 12(9):e0183959. PubMed ID: 28873450
[TBL] [Abstract][Full Text] [Related]
10. The role of discoidin domain receptor 2 in the renal dysfunction of alport syndrome mouse model.
Sannomiya Y; Kaseda S; Kamura M; Yamamoto H; Yamada H; Inamoto M; Kuwazuru J; Niino S; Shuto T; Suico MA; Kai H
Ren Fail; 2021 Dec; 43(1):510-519. PubMed ID: 33706638
[TBL] [Abstract][Full Text] [Related]
11. Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease.
Meehan DT; Delimont D; Cheung L; Zallocchi M; Sansom SC; Holzclaw JD; Rao V; Cosgrove D
Kidney Int; 2009 Nov; 76(9):968-76. PubMed ID: 19710627
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.
Omachi K; Miyakita R; Fukuda R; Kai Y; Suico MA; Yokota T; Kamura M; Shuto T; Kai H
Clin Exp Nephrol; 2017 Dec; 21(6):952-960. PubMed ID: 28176019
[TBL] [Abstract][Full Text] [Related]
13. Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis.
Delimont D; Dufek BM; Meehan DT; Zallocchi M; Gratton MA; Phillips G; Cosgrove D
PLoS One; 2014; 9(6):e99083. PubMed ID: 24915008
[TBL] [Abstract][Full Text] [Related]
14. Pathogenicity of a Human Laminin
Funk SD; Bayer RH; Malone AF; McKee KK; Yurchenco PD; Miner JH
J Am Soc Nephrol; 2018 Mar; 29(3):949-960. PubMed ID: 29263159
[TBL] [Abstract][Full Text] [Related]
15. The Accumulation of VEGFA in the Glomerular Basement Membrane and Its Relationship with Podocyte Injury and Proteinuria in Alport Syndrome.
Wang H; Yue Z; Wu J; Liu T; Mo Y; Jiang X; Sun L
PLoS One; 2015; 10(8):e0135648. PubMed ID: 26274923
[TBL] [Abstract][Full Text] [Related]
16. Human Chorionic Stem Cells: Podocyte Differentiation and Potential for the Treatment of Alport Syndrome.
Moschidou D; Corcelli M; Hau KL; Ekwalla VJ; Behmoaras JV; De Coppi P; David AL; Bou-Gharios G; Cook HT; Pusey CD; Fisk NM; Guillot PV
Stem Cells Dev; 2016 Mar; 25(5):395-404. PubMed ID: 26728561
[TBL] [Abstract][Full Text] [Related]
17. Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.
Steenhard BM; Vanacore R; Friedman D; Zelenchuk A; Stroganova L; Isom K; St John PL; Hudson BG; Abrahamson DR
PLoS One; 2012; 7(12):e50745. PubMed ID: 23236390
[TBL] [Abstract][Full Text] [Related]
18. Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases.
Mitrofanova A; Fontanella A; Tolerico M; Mallela S; Molina David J; Zuo Y; Boulina M; Kim JJ; Santos J; Ge M; Sloan A; Issa W; Gurumani M; Pressly J; Ito M; Kretzler M; Eddy S; Nelson R; Merscher S; Burke G; Fornoni A
J Am Soc Nephrol; 2022 Dec; 33(12):2153-2173. PubMed ID: 36198430
[TBL] [Abstract][Full Text] [Related]
19. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome.
Bae EH; Fang F; Williams VR; Konvalinka A; Zhou X; Patel VB; Song X; John R; Oudit GY; Pei Y; Scholey JW
Kidney Int; 2017 Jun; 91(6):1347-1361. PubMed ID: 28249676
[TBL] [Abstract][Full Text] [Related]
20. Injection of amniotic fluid stem cells delays progression of renal fibrosis.
Sedrakyan S; Da Sacco S; Milanesi A; Shiri L; Petrosyan A; Varimezova R; Warburton D; Lemley KV; De Filippo RE; Perin L
J Am Soc Nephrol; 2012 Apr; 23(4):661-73. PubMed ID: 22302195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
